8/1/2013 11:08:38 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
BOUDRY, Switzerland--(BUSINESS WIRE)--Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data evaluating treatment with REVLIMID® (lenalidomide) in combination with dexamethasone followed by REVLIMID maintenance therapy in patients with high-risk asymptomatic smoldering multiple myeloma were published in the August 1 edition of The New England Journal of Medicine. Smoldering multiple myeloma is an early, asymptomatic form of the disease characterized by a 10% per year risk of progression to symptomatic disease over the first five years.
Help employers find you! Check out all the jobs and post your resume.
comments powered by